Because PDGFRB/EGFR heterodimers were reported to express on bladder cancer cells[14], and the EGF/EGFR pathway played an important role in bladder cancer development[15], [16], PDGFRB was selected for further validation as a candidate biomarker of bladder cancer. The gene discussed is EGFR; the disease is urinary bladder carcinoma.